- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ARCTIC BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| Fr | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Invitation to presentation of Q1 2026 operational update | 2 | Cision News | ||
| 01.04. | Arctic Bioscience AS: Arctic Bioscience - Primary insiders who have provided bank guarantee | - | Oslo Børs | ||
| 01.04. | Arctic Bioscience AS: Arctic Bioscience - New long-term financing | 1 | Oslo Børs | ||
| 19.03. | Arctic Bioscience AS: Arctic Bioscience - New peer-reviewed study shows herring roe phospholipids stimulate anti-inflammatory pathways in cells | - | Oslo Børs | ||
| 26.02. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Q4 2025 Operational update - Positive outlook for 2026 | 3 | Cision News | ||
| 23.02. | Arctic Bioscience AS: Arctic Bioscience - Invitation to presentation of Q4 2025 operational update | 2 | Oslo Børs | ||
| 29.01. | ARCTIC BIOSCIENCE AS: Arctic Bioscience invited to present at the Glaucoma 360 New Horizons Forum | 3 | Cision News | ||
| 18.12.25 | Arctic Bioscience AS: Financial calendar | - | Oslo Børs | ||
| 17.12.25 | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Share capital increase registered | 2 | Cision News | ||
| 12.12.25 | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Board approval of share capital increase related to conversion of debt | 1 | Cision News | ||
| 09.12.25 | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Exercise of right to convert debt and issuance of shares | 1 | Cision News | ||
| 11.11.25 | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Minutes of the Extraordinary General Meeting | 1 | Cision News | ||
| 10.11.25 | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Q3 2025 Operational update - Significant results on systemic inflammation | 5 | Cision News | ||
| 07.11.25 | Arctic Bioscience AS: Arctic Bioscience - Invitation to presentation of Q3 operational update and HeROPA-analyses results | 1 | Oslo Børs | ||
| 04.11.25 | Arctic Bioscience AS: Arctic Bioscience - Analysis on HeROPA study shows statistically significant effects of psoriasis drug candidate HRO350 on inflammation | - | Oslo Børs |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 28,510 | -2,11 % | Qiagen: Von der Übertreibung direkt in eine Untertreibung gelaufen? | Am späten Montagabend legte Qiagen vorläufige Zahlen zum ersten Quartal vor, am gestrigen Dienstag fiel die Aktie daraufhin auf das tiefste Kursniveau seit Herbst 2019. Da die 2026er-Prognose gesenkt... ► Artikel lesen | |
| EVOTEC | 5,005 | -2,63 % | Evotec-Aktie mit +46% - kommt das Comeback? | Die Evotec-Aktie hat zuletzt kräftig zugelegt und stieg um rund +46% an. Damit hat sich das Chartbild deutlich verbessert und eine mögliche Trendwende rückt in den Fokus. Nach der dynamischen Rallye... ► Artikel lesen | |
| ERASCA | 9,260 | -6,37 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| BIONTECH | 86,20 | -1,09 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| STRUCTURE THERAPEUTICS | 41,360 | -4,94 % | Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at | ||
| BEAM THERAPEUTICS | 29,370 | -3,89 % | Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study | ||
| TANGO THERAPEUTICS | 23,420 | -6,80 % | Stifel raises Tango Therapeutics stock price target on drug combo potential | ||
| COGENT BIOSCIENCES | 35,520 | -2,31 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| DESIGN THERAPEUTICS | 16,590 | +29,51 % | Design Therapeutics, Inc.: Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates | Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapiro, M.D., Appointed to Board of Directors, Strengthening Clinical and Regulatory Expertise Cash and... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 52,76 | -2,02 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $930 - $945 million -- KPL-387... ► Artikel lesen | |
| ADMA BIOLOGICS | 10,565 | -2,98 % | Summers Value Fund adds TBPH, exits ADMA among Q1 moves | ||
| SUMMIT THERAPEUTICS | 20,840 | -1,98 % | Summit Therapeutics leads all large-cap healthcare stocks in YoY CapEx growth | ||
| MODERNA | 39,135 | -2,76 % | Moderna, Inc.: Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate | Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / ACCESS Newswire / April... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 22,490 | -3,44 % | Arcutis Biotherapeutics, Inc.: Arcutis' ZORYVE (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines | Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitorAtopic... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 81,72 | -4,15 % | Apogee Therapeutics Inc. (APGE): Primary Challenger to Established Blockbusters |
ARCTIC BIOSCIENCE AS gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -2,83 % bei einem Aktienkurs von 0,240 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCTIC BIOSCIENCE AS finden Sie auf Wallstreet Online.